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Abstract
Background: Epilepsy is a severe neurological disorder with huge psychological, social, and economic
consequences, including premature deaths and loss of productivity. Sub-Saharan Africa carries the highest burden
of epilepsy. The management of epilepsy in Cameroon remains unsatisfactory due to poor identification of cases
and a limited knowledge of the distribution of the disease. The objective of this study was to determine whether
community drug distributors (CDDs) - volunteers selected by their communities to distribute ivermectin against
onchocerciasis and who have been proven efficient to deliver other health interventions such as insecticide-treated
bed nets to prevent malaria, vitamin A tablets, and albendazole to treat soil transmitted helminthiasis - can be used
to reliably identify people living with epilepsy to promote better management of cases.
Methods: This study was carried out in three health Districts in Cameroon. An exhaustive house to house census
was carried out by trained CDDs under the supervision of local nurses. In each household, all suspected cases of
epilepsy were identified. In each health district, five communities were randomly selected for a second census by
trained health personnel (research team). The results of the two censuses were compared for verification purposes.
Results: A total of 53,005 people was registered in the 190 communities surveyed with 794 (1.4%) individuals
identified as suspected cases of epilepsy (SCE) by the CDDs. In the 15 communities where the SCE census was
verified, the average ratio between the number of suspected cases of epilepsy reported in a community by the
research team and that reported by the CDDs was 1.1; this ratio was < 0.8 and > 1.2 in 6 communities.
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Conclusions: The results of this study suggest that CDDs, who are present in about 200,000 communities in 31 Sub
Saharan African countries where onchocerciasis is endemic, can be successfully used to assess epilepsy prevalence,
and therefore map epilepsy in many African countries.
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Background
Epilepsy is a disorder characterized by an enduring pre-
disposition to generate epileptic seizures, the latter
being defined as a transient occurrence of signs and/or
symptoms due to abnormal excessive or synchronous
neuronal activity in the brain [1]. Epilepsy is associated
with significant psychological, neurobiological, cogni-
tive, social, and economic consequences including in-
creased health care needs, premature deaths and loss of
productivity. The number of people suffering from life-
time epilepsy (i.e. with a history of epilepsy, regardless
of treatment or recent seizure activity) is estimated to
be 6.8 million in high-income countries and 62 million
in low- and middle-income countries (45 and 17 million in
rural and urban areas, respectively) [2]. The numbers of
people with active epilepsy (i.e. those who may benefit
from treatment) are estimated at 5.7 and 27 million in
high-income and low- and middle-income countries,
respectively [2]. Epilepsy represents 0.7% of the global
burden of disease, as assessed by disability-adjusted life
years (DALY) [3]. The median annual incidence of epilepsy
- estimated to be 50.4/100,000 - is significantly higher in
low- and middle-income countries (81.7/100,000) than in
high-income countries (45.0/100,000) [4].
In Sub-Saharan Africa, the prevalence of epilepsy, as
well as the excess mortality associated with this condi-
tion, are particularly high [5–8]. In a rural area in
Cameroon, for instance, the relative risk of dying within
10 years was increased by 6.2-fold [95% CI 2.7; 14.1] in
SCE [9]. In Africa, the management of epilepsy faces
many difficulties, including poor availability of, and ac-
cess to, antiepileptic drugs (AED) and the lack of infor-
mation about disease prevalence and thus the amount of
AED needed [10]. The latter issue is largely due to the
paucity of trained health personnel able to accurately
diagnose the condition [11, 12]. In addition, there is
wide variation in the prevalence and incidence rates be-
tween and within countries, mainly due to differences in
the distribution of epilepsy risk factors [5–7, 13–15]. It
is therefore important to identify areas where the burden
of epilepsy is particularly high to appropriately allocate
personnel and financial resources and to identify local
risk factors for epilepsy (particularly infectious diseases)
which could be targeted for specific control measures.
In most African countries, conventional door-to-door sur-
veys for epilepsy are often limited to selected communities.
Rapid assessment strategies involving the communities
themselves to assess the number of SCE could expand the
epidemiological coverage of these surveys. Such strategies,
including census by key informants or methods known as
“participatory rural appraisal”, have been tested in several
countries [16–19]. Each of these methods has advantages
and limitations, even when combined in a multi-stage
screening approach [20, 21]. However, they might produce
rough information on regional variation in the prevalence of
epilepsy and help to identify local risk factors.
From more than 20 years, a so-called “community-di-
rected” strategy was applied to deliver drugs as part of
international programmes targeting neglected tropical dis-
eases (NTD). This approach was first tested against oncho-
cerciasis, a parasitic disease due to Onchocerca volvulus
which can cause blindness and severe skin manifestations.
Community drug distributors (CDDs) living in the en-
demic communities and selected by community members
are in charge of distributing ivermectin (Mectizan®) tablets
once or twice a year to the whole population [22]. This
decentralized, sustainable and cost-effective strategy led to
a dramatic decrease in the level of infection, and probably
its elimination in many foci [23]. As community-directed
treatment with ivermectin (CDTI) proved to be successful,
investigations were conducted to evaluate whether other
community-directed interventions (CDI) could be applied
[24–27]. Nowadays, CDDs are involved not only in oncho-
cerciasis control, but also in distribution of ivermectin plus
albendazole against lymphatic filariasis, of albendazole or
mebendazole against soil-transmitted helminths, of prazi-
quantel against schistosomiasis, and of vitamin A to pre-
vent complications of deficiency [28, 29]. Involvement of
CDDs in more complex interventions against malaria, tu-
berculosis and HIV has also been tested or considered in
some countries [30–32].
In addition to the delivery of drugs, vaccines or
mosquito-nets, community volunteers can help identify-
ing subjects with visual impairment [33–37], Buruli
ulcer, trachomatous trichiasis, and visceral leishmaniasis
for referral for surgery or treatment [38–40], and in de-
tecting cases of poliomyelitis [41–43] and Guinea worm
[44] in conjunction with ongoing elimination programs.
The objective of the present study, conducted in 2012,
was to evaluate the ability of CDDs already involved in
CDTI against onchocerciasis to carry out a reliable cen-
sus of SCE living in their community.
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Methods
Study area
In Cameroon, the health system at the peripheral level is
organized into Health Districts (HDs) and Health Areas
(HAs). The HD is the operational unit for the imple-
mentation of public health programs. It is comprised of
HAs, defined by the presence of an integrated health
center covering an average of 10 communities. The
study was carried out in the Ndikiniméki and Monatélé
HDs (Centre region), and in Pouma HD (Littoral re-
gion). The Monatélé and Pouma HDs are limited to the
north by the Sanaga River, and the Ndikiniméki HD is
limited to the east by the Mbam River, the main tribu-
tary of the Sanaga. These three HDs are highly endemic
for onchocerciasis [45, 46] and CDTI has been in place
since 1999. An association between onchocerciasis and
epilepsy was demonstrated in the neighboring Bafia HD
[47]. Much of the treatment and care for epilepsy in the
study HDs is supported by caregivers associated with
religious organizations. All communities in all HAs in
the selected HDs were included in the study.
Study design
The study was conducted from 2011 to 2012 in areas of
Cameroon with historically high prevalences of epilepsy
[48–50]. Given the CDDs’ experience visiting households
for many years, we assumed that they had established a
bond of trust with the population to whom they provide
various type of community cares and would therefore be
able to gather reliable data, even on a stigmatized disease
such as epilepsy that people are usually hiding [8]. To
assess accuracy, the data collected by the CDDs were
compared with those obtained subsequently by the team
of the Centre for Research on Filariasis and other Trop-
ical Diseases (CRFilMT), so-called research team. During
the verification by the research team, all surveyed com-
munities were geo-localized (geographical coordinates
were collected at the center of each community) using
the Global Position System (GPS) in order to map the
distribution of epilepsy in the study HDs.
Training of CDDs and health personnel
The process started with the sensitization of the admin-
istrative, health, and traditional authorities, as well as the
general population, about the procedures and objectives
of the study. All CDDs of each health district attended
the training session organized by the District Medical
Officer and the nurse head of the Health Center. The
CDDs, the nurses head of Health Centers, and a member
of the HD office were trained for 2 days by the research
team on the objectives and the procedures of the study.
Participants in the training received basic information
on the etiology and various types of epilepsy, the ways to
prevent stigmatization of SCE, and how to conduct a
census of the general population, record the SCE and
complete the registration forms. Sessions were also orga-
nized in the Health Centers to provide practical experi-
ence to surveyors.
The training relied on the questionnaire developed by
Preux while carrying out studies on epilepsy in tropical
countries [50] (see questions 7–8 in Additional file 1).
Based on this questionnaire, simulation and explanation
of different type of crises were done, in order to capaci-
tate them to explain to the populations and to be able to
collect the types of crisis in communities. The different
type of crises explained were: (i) the falls with loss of
consciousness, (ii) shaking or uncontrollable movements
of one or more limbs, (iii) loss of contact with the entou-
rage, and (iv) strange body sensations, visual illusions,
auditory or olfactory (odors) [51].
Census procedures for the CDDs
In each study community, an exhaustive house to house
survey was carried out over a period of 1 week by the
trained CDDs. Each CDD recorded information from 20
households, representing approximately 100 inhabitants.
The process was supervised by the nurse head of the
Health Center for the community, who did not formally
participate in the census. In each household, the head of
the household (HoH) (or his/her spouse/partner or any
other adult family member who was able to provide ac-
curate answers if the latter was absent during the survey)
was asked to provide the name, age and occupation of
each household member, including those who were tem-
porally absent during the visit of the survey teams (either
CDDs or research team). This information was recorded
on a specific census form (Additional file 1).
Next, the HoH was asked whether any household mem-
ber suffered or is suffering from epilepsy. In the case of a
positive answer, the standardized questions to define the
type of crises [50] were asked to elicit demographic data,
as well as the circumstances and presentation of the epi-
leptic crisis (Additional file 1). According to the criteria of
the International League Against Epilepsy at the time of
the study, suspected cases of epilepsy (SCE) were defined
by a history of two or more unprovoked seizures occur-
ring at least 24 h apart [52]. Isolated seizures associated
with fever were excluded.
Verification by the trained health personnel (research team)
In each of the three HDs, five communities were ran-
domly selected by drawing of lot for verification of the
number of SCEs, without any assumption on a potential
difference between communities. For time constraint
reasons, only one of these communities was used to
confirm the census data for the total population in each
HD. The verification team consisted of trained health
personnel (medical doctors and nurses specialized in
Kamgno et al. BMC Public Health          (2020) 20:871 Page 3 of 11
public health), and the census procedures used for verifi-
cation, both for the general population and the SCEs, were
identical to those used by the CDDs, though independent.
Data analysis
The prevalence of epilepsy with 95% confidence intervals
estimated from the data collected by CDDs in each com-
munity were calculated at both the HD and HA levels. A
concordance analysis was performed to compare the
performance of CDDs and that of the trained health
personnel in enumerating the general populations and
SCE [53]. Intrinsic (sensitivity, specificity) and extrinsic
(positive and negative predictive values) parameters were
used to (i) compare the census of the general population
in each community between CDDs and research team,
and (ii) assess whether the proportions of SCE by CDDs
were similar to those by the research team, the results
obtained by the trained personnel being used as the ref-
erence. Also, Kappa statistics was used to evaluate the
concordance of census between CDDs and research
team in three communities where both teams conducted
census of general population and SCE [53]. All statistical
analyses were performed using STATA 12.1 software
(STATA Corporation, college Station, TX, USA). Since
epilepsy is usually associated with onchocerciasis, CDDs-
based point prevalence of epilepsy was illustrated accord-
ing to altitude and distance to hydrographic network (both
indicative of black fly breeding sites) using the software
ArcGIS, version 10.2, ESRI Inc.
Results
Prevalence of epilepsy measured by the CDDs
The census was conducted in 185 communities located
in 19 HAs (8 in Monatélé HD, 6 in Ndikiniméki HD and
5 in Pouma HD) (Table 1) by a total of 490 CDDs
among which 62.0% were males. The median number of
people covered by a CDD was 97.3, with an interquartile
range (IQR) equal to 93.0. In 1–2 weeks (depending on
the population size), the CDDs registered a total of 53,
044 people in the targeted communities and recorded
766 SCEs (1.4%). The prevalence of SCEs was very vari-
able within the HDs and even within specific HAs. The
mean prevalence of SCEs was higher than 2.0% in three
HAs of the Monatélé HD (Eyeng-Meyong, Monatélé and
Table 1 Number of villages surveyed in each health area, and total population and suspected cases of epilepsy (SCE) recorded by
the CDDs in these villages
Health
district






Percentage of SCE per community
Mean Min Max
Monatélé Eyeng-Meyong 4 821 22 2.7 0 5.2
Monatélé 23 10,214 238 2.3 0 8.1
Mvomekak II 10 4321 40 0.9 0 1.7
Ngomo 6 2593 19 0.7 0.3 1.6
Nkog-Bong 6 3556 26 0.7 0 1.8
Nkolkosse 9 3439 31 0.9 0 3.3
Nlong-Bong 12 3368 109 3.2 1.9 6.0
Tala 8 2506 49 2.0 0.9 4.8
All 78 30,818 534 1.7 0 8.1
Ndikiniméki Boutourou 6 2093 39 1.9 0 4.6
Makenene 9 3721 36 1.0 0 2.5
Ndikiniméki 22 5241 41 0.8 0 7.5
Ndokowanen 3 951 0 0 0 0
Nitoukou 13 1376 1 0.1 0 0.6
Nyokon 6 1859 24 1.3 0 2.8
All 59 15,241 141 0.9 0 7.5
Pouma Makob Log-Bako 10 1528 20 1.3 0 6.1
Nkonga 7 1184 28 2.4 0 8.9
Pouma-Centre 10 1646 11 0.7 0 4.7
Saint-André 12 1555 7 0.5 0 1.9
Song Simouth 9 1072 25 2.3 0 6.6
All 48 6985 91 1.3 0 8.9
All 185 53,044 766 1.4 0 8.9
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Nlong-Bong) and two HAs of the Pouma HD (Nkonga
and Song Simouth) (Table 1). Figures 1, 2 and 3 show
the location of each surveyed community, its distance
from the hydrographic network (especially the Simulium
breeding sites) and the prevalence of SCEs.
At the community level, 7 of the 78 communities
surveyed in the Monatélé HD had a prevalence of SCE
exceeding 5.0%, with the highest values in Levem (8.1%),
Mong (6.9%), Nkol-Melong (6.5%) and Nlongbong II
(6.0%) (see data per community in Additional file 2). In
the same HD, the prevalences ranged from 3.0 to 5.0%
in 15 other communities. In the Ndikiniméki HD, only
one of the 59 communities surveyed had a prevalence of
SCE exceeding 5.0% (Nomena: 7.6%) and 3 others had
prevalences between 3.0 and 5.0% (Kiboum I: 4.7%; and
Kiboum II: 4.4% and Ndikoti: 4.8%). In Pouma HD (48
communities surveyed), the prevalence of SCE exceeded
5.0% in 4 communities (Logbassom: 8.9%, Sakbayeme
III: 6.6%; Ngompem-Nkanla: 6.1% and Sakbayeme II:
5.6%) and ranged between 3.0 and 5.0% in one commu-
nity (Pouma Centre administratif: 4.8%).
Different types of crises were reported by CDDs,
including falls with loss of consciousness (79.8%), shak-
ing or uncontrollable movements of one or more limbs
(62.7%), loss of contact with the entourage (67.2%), and
strange body sensations, visual illusions, auditory or
olfactory (40.7%).
Validation survey by trained health personnel
The validation survey by the research team aimed at
verifying the census of the general population as well as
that of the SCE. This validation was conducted approxi-
mately 3 months after the census by CDDs, and was
organized in a total of 15 communities (among which
the census of the general population was verified in
three of them), with a total population of 5895 inhabi-
tants, corresponding to 11.1% of the total population of
the three health districts.
In the three communities (one in each health district)
selected for verification of the general population census
data, the results obtained by CDDs were in general lower
than those obtained by the trained health personnel (864
Fig. 1 Prevalence of CDDs-based suspected cases of epilepsy in the Monatélé Health District (Centre Region, Cameroon). Each dot represents a
point prevalence of epilepsy at community level and is represented according to altitude and distance to hydrographic network both indicative
of black fly (vector of Onchocerca volvulus) breeding sites
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vs 1040 people, respectively), including 342 vs. 595
people in Kiboum I (Ndikiniméki HD), and 230 vs. 252
people in Nkondjock II (Pouma HD). The difference was
particularly marked in Kiboum I, where 42.5% of the
population was missed by the CDDs.
In contrast, in the 15 communities (five in each health
district) where the number of SCEs was verified by the
research team, the difference between the number of
cases recorded by the CDDs and that recorded by the
health personnel exceeded two in only one community,
Nkolkosse (columns CDD+ and Team+ in Table 2). The
kappa coefficient (0.91) show almost perfect agreement
between census performed by CDDs and research team.
The number of SCE recorded by the health personnel
was higher than that recorded by the CDDs in 8 com-
munities, the same in 2 communities, and lower in 5
communities (Table 2). The average ratio between the
number of SCE reported in a community by the research
team and that reported by the CDDs was 1.1 (range 0.5
to 2.0, with a ratio < 0.8 and > 1.2 in only 6 communi-
ties). At HD level, the ratio was higher (and thus more
SCEs were missed by the CDDs) in Monatélé HD (1.4)
than in Ndikiniméki and Pouma HDs (1.1 in both HD).
The sensitivity of diagnosis made by the CDDs (using
the health personnel as the gold standard) was 48.3%,
ranging from 42.5% in Nidikiniméki HD to 60.0% in
Pouma HD, with a positive predictive value of only
55.1%, ranging from 48.6 to 68% depending on the HD.
The most frequent type of crisis reported by the valid-
ation team were tonic-clonic crises (79.8%), SCEs exhi-
biting partial crises and with absence of crises were also
reported in 10.4 and 9.8% of cases, respectively.
Discussion
Epilepsy is a very common condition in Africa, where
some of the highest prevalence and burden in the world
have been recorded. This is likely due to an important
cocktail of potential causes of this condition in Africa,
such as (i) viral, bacterial and parasitic infections with
potential neurological involvement [6, 54–59], as well as
(ii) cranial trauma consecutive to pregnancy and/or
childbirth complications, and road accidents [60, 61].
Compounding the high prevalence and burden of epi-
lepsy in Africa is the large treatment gap, defined as the
Fig. 2 Prevalence of CDDs-based suspected cases of epilepsy in the Ndikinimeki Health District (Centre Region, Cameroon). Each dot represents a
point prevalence of epilepsy at community level and is represented according to altitude and distance to hydrographic network both indicative
of black fly (vector of Onchocerca volvulus) breeding sites
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proportion of people with epilepsy who require treat-
ment but do not receive it. Indeed, a systematic review
showed that this gap exceeds 75% in low-income coun-
tries, and that it is greater than 95% in 7 of the 11
African countries included in the study [62]. The main
causes of this treatment gap have been related to the
health systems in Africa, which are plagued by inad-
equate skilled manpower, high costs of treatment and
the unavailability of drugs [63]. In this context, it is im-
portant to identify areas where the prevalence of epilepsy
is particularly high, so that efforts can be focused where
patients’ needs are the greatest and local preventable
causes of epilepsy may be identified.
Published data on the distribution of epilepsy in
Cameroon is very scanty and limited to a few communi-
ties. A major factor limiting the availability of data is the
Fig. 3 Prevalence of CDDs-based suspected cases of epilepsy in the Pouma Health District (Littoral Region, Cameroon). Each dot represents a
point prevalence of epilepsy at community level and is represented according to altitude and distance to hydrographic network both indicative
of black fly (vector of Onchocerca volvulus) breeding sites
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paucity of personnel to conduct epidemiological assess-
ments. To address this problem, this study aimed to evalu-
ate the capacity of CDDs to conduct the census of SCE at
the same time as the general census of population. Discus-
sions conducted during the training confirmed the results
of other studies [64–67], demonstrating that most people
in the communities are well aware of the disease and
suggesting that CDDs could easily conduct the census of
SCEs.
The present study demonstrated that the sensitivity of
CDD assessment to identify SCEs was relatively low.
However, since the number of individuals falsely sus-
pected to be epileptic and the number of SCE who were
missed by the CDDs were also low, the prevalences of
epilepsy calculated from data collected by the CDDs
were not statistically different from those obtained by
the research team. However, it is worth to mention that
the number of SCEs recorded by both CDDs and the re-
search team was quite low, and the power of the com-
parison test likely low. Despite this limitation, it is clear
that CDDs can provide, at relatively low cost, a picture
of the burden of epilepsy at the level of communities,
HAs or HDs, and reveal areas where the prevalences are
particularly high. Indeed, CDDs or other community
health workers could be used to identify SCEs at first
line, and the latter referred to health care professionals
for a clinical diagnosis of epilepsy for SCE confirmation
and furthermore appropriate treatments. This approach
has been recently suggested for a comprehensive man-
agement of epilepsy in onchocerciasis-endemic areas,
and was based on a decentralized epilepsy care, with
simplified approaches for the diagnosis and treatment of
epilepsy by non-physicians, under the supervision of
physicians or specialists [68]. It is also important to note
that the population census (measurement of the denomin-
ator) has to be carefully checked because in some instances
the population size can be under- or overestimated by the
CDDs. The census of the general population and of SCE by
CDDs is however perfectible and can be refined through
additional trainings and exercises. Indeed, census of popula-
tion is conducted at a yearly basis by CDDs in the frame-
work of onchocerciasis control or other community public
health interventions, given them the opportunity to sharpen
their census of SCE and adjust their denominators.
Table 2 Suspected cases of epilepsy (and prevalence of epilepsy) recorded by the CDDs (CDD+) and by the research team (Team+)
in the villages where the verification was conducted, resulting prevalences, and ratio between the prevalences






Team+CDD+ Team+ CDD Team
Monatélé Eyen-Meyong Nkol-Feb** 292 3 4 1.03 1.37 1.3 2 1 2
Mvomekak Ebolmongo II 626 11 10 1.76 1.60 0.9 8 3 2
Ngomo Ebanga 513 3 5 0.58 0.97 1.7 3 0 2
Nkog-Bong Nkog-Bong 896 3 5 0.33 0.56 1.7 3 0 2
Nkolkosse Nkolkosse 512 5 10 0.98 1.95 2.0 1 4 9
All 2839 25 34 0.88 1.20 1.4 17 8 17
Ndikiniméki Boutourou Boneck I 449 10 12 2.23 2.67 1.2 3 7 9
Boutourou Kiboum I** 342 15 17 4.39 4.97 1.1 9 6 8
Makenéné Mock Sud 459 6 7 1.31 1.53 1.2 3 3 4
Ndikiniméki Ndikitole 363 4 2 1.10 0.55 0.5 2 2 0
Nyokon Kinding Ndjabi 339 0 2 0 0.59 NA 0 0 2
All 1952 35 40 1.79 2.05 1.1 17 18 23
Pouma Makob Lob Bako Ngompem-Nkanla 114 7 6 6.14 5.26 0.9 4 3 2
Nkonga Nkonga A 152 1 0 0.66 0 0 0 1 0
Pouma Centre Song Woga 325 2 2 0.62 0.62 1.0 2 0 0
Saint André Nkondjock II** 230 3 3 1.30 1.30 1.0 3 0 0
Song Simouth Sakbayeme II 283 5 4 1.77 1.41 0.8 0 5 4
All 1104 18 15 1.63 1.36 0.8 9 9 6
ALL 5895 78 89 1.32 1.51 1.1 43 35 46
* Population recorded by the CDDs
** Villages where both the population census and the census of SCE were verified by the project team
§ SCE recorded by both the CDDs and the research team (CDD+ Team+)
μ SCE recorded by the CDDs only (CDD+ Team-)
β SCE recorded by the research team only (CDD- Team+)
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The prevalences of SCEs identified during this study
were very high in some of the HAs surveyed, particularly
in Monatélé and Ndikiminéki HDs. These results are in
accordance with previous results in the region [52].
Considering the sociologic and demographic impacts of
epilepsy in the neighboring Bafia HD [8], special inter-
ventions are clearly required in the study area. Given the
previously demonstrated relationship between onchocer-
ciasis and epilepsy [48], CDTI should certainly be rein-
forced and, over time, may reduce the incidence of
epilepsy of this region. Since the effect of ivermectin on
pre-existing epilepsy is less evident, better access to anti-
epileptic drugs (AEDs) should also be prioritized. How-
ever, the prevalence of epilepsy reported in this study is
in general low as compared to those reported in the
review by Bugembe and colleagues [65]. It is worth to
mention that these data were collected after about 15
years of ivermectin-based mass treatments against on-
chocerciasis. There are mounting evidences of a strong
relationship between onchocerciasis and epilepsy, and a
temporal relationship between these two diseases has
been recently demonstrated [66]. This likely means that
if the prevalence and intensity of onchocerciasis infec-
tion decreased as a consequence of mass treatments, the
incidence of epilepsy might follow the same trends. In
addition, it was recently demonstrated that the SCE preva-
lence decreased after multiple rounds of ivermectin-based
MDA [69, 70], the reduction of Onchocerca volvulus
transmission recently reported leading to a decrease in the
number of new cases of epilepsy, and consequently to an
age shift among SCE observed [71].
Limitation
As stated above, slight discrepancies were observed be-
tween the census of the general population as well as
that of SCE reported by CDDs and research team. These
discrepancies can be explained, at least partly, by the fact
that (i) people interviewed by the CDDs and the research
team in each household were not always the same. The
weight of these errors in census either of general popula-
tion or SCE cannot be estimated since the information
was not collected; (ii) verification censuses were con-
ducted approximately 3 months after the censuses by
CDDs, and slight variation in the populations, both gen-
eral and that of SCEs, consecutive to births, deaths or
migrations might be expected.
It is likely that these discrepancies can be larger if one
wants to scale up this strategy. As such, data reported by
the CDDs are not 100% reliable, some SCE needing
treatment might be missed, and some individuals not
suffering from epilepsy wrongly enrolled. To overcome
this situation, a validation of SCE identified by CDDs
should be done by trained health personnel before initi-
ating treatments. Once initiated, the “ripple effect” of
these treatments might be useful to identify missing
cases who might have been hiding in communities.
Conclusions
This study revealed that community health workers or
CDDs may be able to perform the census of SCE, espe-
cially in rural areas, though some substantial differences
were sometimes found while validating their work and
the power of comparison test was low. More research in
other settings should therefore be conducted to confirm
this observation. As demonstrated for other health inter-
ventions, training and monitoring are key to the collec-
tion of reliable data. Should this strategy be used at a
larger scale, identification of areas where specific etiolo-
gies of epilepsy are present could help guide policy
makers in prioritizing areas of greatest need. Finally, the
use of community personnel as a repository for AEDs at
the community level supervised by health personnel
should be explored since this approach might help in-
creasing epilepsy treatment coverage and compliance.
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